泊沙康唑
毛霉病
合子菌病
两性霉素B
医学
抗真菌
药物治疗
疾病
根霉
外科
内科学
皮肤病科
重症监护医学
生物
食品科学
发酵
作者
Jörg Janne Vehreschild,Andrea Birtel,Maria J. G. T. Vehreschild,Blasius Liss,Fedja Farowski,Matthias Kochanek,Michal K. Sieniawski,Angela Steinbach,Kerstin Wahlers,Gerd Fätkenheuer,Oliver A. Cornely
标识
DOI:10.3109/1040841x.2012.711741
摘要
Mucormycosis is an emerging invasive fungal infection, primarily affecting immunocompromised patients. The disease is difficult to diagnose and mortality reaches 40% even if treated adequately. Depending on site of infection and risk factors, surgical debridement in combination with systemically active antifungal drugs are the mainstay treatment strategies. Lipid-based amphotericin B is the treatment of choice for first-line therapy while posaconazole may be a promising alternative. We performed a PubMed search on reports of patients with mucormycosis treated with posaconazole. From 2003 to 2011, 96 cases have been published. Diagnosis was based on histology alone in 2 (2.1%) and microbiological evidence in 67 (69.8%), while no data on the diagnostic approach was reported in 27 (28.1%) patients. The most frequent pathogens were Rhizopus spp. (31.2%), followed by Mucor spp. (14.6%). The site of infection was predominantly rhino-orbital (38.5%, of which 43% also had central nervous system [CNS] involvement), followed by disseminated disease (22.1%). A complete response was achieved in 62 (64.6%), partial response in 7 (7.3%) patients, and stable disease in 1 (1%). Overall mortality was 24% (lacking data for three patients). In published case reports on posaconazole treatment for mucormycosis, the drug was frequently and successfully used in combination or as second line therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI